In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions Industry Update: Interim 503A and 503B Bulks Lists New Revisions FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling